What is it about?
We evaluated a series of new naphthoquinone derivatives, specifically 3,3'-((1-aryl-1H-1,2,3-triazol-4-yl)methylene)bis(2-hydroxynaphthalene-1,4-diones) and 7-(1-aryl-1H-1,2,3-triazol-4-yl)-5H-dibenzo[b,h]xanthene-5,6,8,13(7H)-tetraones. We found that compound 12a, a triazole-linked xanthene, is a promising candidate for an anticancer drug because it increases ROS production and damages the cell membrane in cancer cells. Compound 12a showed selective effects on cancer cells without affecting normal cells, unlike the commonly used drug doxorubicin, which affected both cell types. Further evaluation revealed that compound 12a reduces ATP and DNA content, explaining its antiproliferative effects on breast cancer cells.
Featured Image
Why is it important?
new compound is considered a significant candidate for an anticancer drug.
Read the Original
This page is a summary of: Design, Synthesis and Biological Evaluation of 1H-1,2,3-Triazole-Linked-1H-Dibenzo[b,h]xanthenes as Inductors of ROS-Mediated Apoptosis in the Breast Cancer Cell Line MCF-7, Medicinal Chemistry, February 2019, Bentham Science Publishers,
DOI: 10.2174/1573406414666180524071409.
You can read the full text:
Contributors
The following have contributed to this page
